<DOC>
	<DOCNO>NCT01223365</DOCNO>
	<brief_summary>The primary objective study evaluate safety hydrocodone extended-release tablet use 12-month period patient chronic pain , assessed adverse event , clinical laboratory result , vital sign measurement , electrocardiogram result , physical examination finding , pure tone audiometry , concomitant medication usage .</brief_summary>
	<brief_title>Study Evaluate Long-Term Safety Hydrocodone Bitartrate Extended-Release Tablets ( CEP-33237 ) Patients Who Require Opioid Treatment Extended Period Time</brief_title>
	<detailed_description>This Phase 3 , open-label , nonrandomized study consist screening period , open label titration period , 52 week , long term , open-label treatment period patient chronic pain . Patients eligible participate study complete study C33237/3079 ( NCT01240863 ) ( patient hereafter refer rollover patient ) participate study 3079 ( patient hereafter refer either new opioid na√Øve new opioid experience patient ) .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<criteria>The patient must willing able successfully selfadminister study drug , comply study restriction , return clinic schedule study visit specify protocol . The patient either complete Cephalon study 3079 chronic pain least 3 month duration prior enter study associate following condition : diabetic peripheral neuropathy , postherpetic neuralgia , traumatic injury , complex regional pain syndrome , back pain , neck pain , osteoarthritis , rheumatoid arthritis . Patients painful condition may qualify study permission Cephalon medical monitor designee . Those patient complete 12week , doubleblind , placebocontrolled , randomize study ( study 3079 ) willing retitrate study drug effective dose hydrocodone extendedrelease tablet eligible enter study . The patient able speak English , willing provide write informed consent , sign write opioid agreement , participate study . The patient 18 80 year age ( inclusive ) time enter previous study ( study 3079 ) . Women childbearing potential ( surgically sterile 2 year postmenopausal ) , must use medically accept method contraception must agree continue use method duration study 30 day participation study , negative pregnancy test screening . Patients enrol study 3079 complete 12week , doubleblind , placebocontrolled , randomize study may enrol study . The patient know suspected hypersensitivity , allergy , contraindication study drug excipients . The patient recent history ( within 5 year ) current evidence alcohol substance abuse . The patient medical psychiatric condition/disease , opinion investigator , would compromise collect data . The patient take total ( i.e. , include aroundthe clock [ ATC ] rescue medication ) 135 mg/day oxycodone equivalent 14 day prior screen . The patient history suicidality . The patient diagnosis chronic headache migraine primary painful condition study . The patient expect surgery study anticipate surgery alleviate patient 's pain . The patient pregnant lactating . The patient active malignancy . The patient human immunodeficiency virus ( HIV ) . In judgment investigator , patient clinically significant deviation normal physical examination and/or clinical laboratory test value . The patient cardiopulmonary disease would , opinion investigator , significantly increase risk treatment potent synthetic opioids . The patient participate study involve investigational drug previous 30 day ( exclude participate study 3079 ) . The patient receive monoamine oxidase inhibitor ( MAOI ) within 14 day first treatment study drug . The patient medical condition receive concomitant medication/therapy ( e.g. , regional nerve block ) would , opinion investigator , compromise patient 's safety compliance study protocol , compromise collect data . The patient involve active litigation regard chronic pain currently treat . The patient positive urine drug screen ( UDS ) illicit substance medication prescribe physician currently treat chronic pain . The investigator feels patient suitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>moderate severe pain</keyword>
	<keyword>diabetic peripheral neuropathy</keyword>
	<keyword>postherpetic neuralgia</keyword>
	<keyword>traumatic injury</keyword>
	<keyword>complex regional pain syndrome</keyword>
	<keyword>back pain</keyword>
	<keyword>neck pain</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>rheumatoid arthritis</keyword>
</DOC>